Clinical Trial Update: Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

View source ↗

Summary

A completed real-world study evaluating apixaban for prevention of stroke and systemic embolism in adults with atrial fibrillation in France.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Anticoagulation | Status: COMPLETED